德克萨米他预处理增强了叶酸功能化的输送系统,用于增强肺癌治疗
Ying Zhao1, Changhao Jia2, Zhixin Yao3
1Department of Pharmacy, Children's Hospital of Soochow University, Suzhou 215003, China.
Molecular pharmaceutics
|February 12, 2024
概括
这项研究引入了一种连续疗法,将甲 (Dex) 预处理与携带多克苏鲁比 (DOX) 的叶酸 (FA) 功能化纳米颗粒结合起来,以提高癌症治疗的疗效. 这种方法放大叶酸受体α (FRα) 和抑制免疫反应,导致优异的瘤抑制.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 叶酸 (FA) 功能化纳米粒子 (NP) 针对癌症治疗的叶酸受体α (FRα).
- 治疗疗效受到瘤中可变FRα表达和免疫球蛋白水平的限制.
研究的目的:
- 开发一种使用德克萨米他松 (Dex) 来放大FRα和降低免疫抑制的序列疗法,结合FA功能化多克索鲁比 (DOX) 微粒,用于协同抑制瘤.
主要方法:
- 从奇托寡糖化物,改性胆固醇和2,3-二甲基胺无水化物中制造出pH/降解反应的FA功能化 (FCSD).
- 服用Dex预处理以降低血清IgM并增加M109细胞上的FRα.
- 利用FCSD/DOX NP进行向药物输送,有效载荷释放由瘤微环境刺激 (pHe,GSH) 触发.
主要成果:
- 德克斯的预治疗增强了FRα向和降低了免疫抑制.
- 在FCSD/DOX NP中,药物输送和释放动力学得到改善.
- 与单一治疗相比,顺序治疗显示出明显优异的瘤抑制.
结论:
- 结合Dex预治疗和向化疗与FCSD/DOX NP的顺序治疗为FRα阳性肺癌提供了一个有希望的策略.
- 这种方法通过优化药物向和输送来协同增强治疗结果.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164